Omeros (OMER) Competitors $6.76 -0.11 (-1.60%) As of 04/16/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OMER vs. PCRX, NKTR, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMYShould you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol-Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry. Omeros vs. Pacira BioSciences Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Pacira BioSciences (NASDAQ:PCRX) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking. Does the MarketBeat Community prefer PCRX or OMER? Pacira BioSciences received 81 more outperform votes than Omeros when rated by MarketBeat users. Likewise, 71.55% of users gave Pacira BioSciences an outperform vote while only 70.73% of users gave Omeros an outperform vote. CompanyUnderperformOutperformPacira BioSciencesOutperform Votes83071.55% Underperform Votes33028.45% OmerosOutperform Votes74970.73% Underperform Votes31029.27% Is PCRX or OMER more profitable? Omeros has a net margin of 0.00% compared to Pacira BioSciences' net margin of -13.07%. Pacira BioSciences' return on equity of 13.42% beat Omeros' return on equity.Company Net Margins Return on Equity Return on Assets Pacira BioSciences-13.07% 13.42% 7.19% Omeros N/A N/A -49.92% Do insiders & institutionals believe in PCRX or OMER? 99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 12.3% of Omeros shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer PCRX or OMER? Pacira BioSciences presently has a consensus target price of $26.67, indicating a potential upside of 8.98%. Omeros has a consensus target price of $22.50, indicating a potential upside of 232.84%. Given Omeros' stronger consensus rating and higher probable upside, analysts plainly believe Omeros is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacira BioSciences 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33Omeros 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 Does the media favor PCRX or OMER? In the previous week, Pacira BioSciences had 6 more articles in the media than Omeros. MarketBeat recorded 14 mentions for Pacira BioSciences and 8 mentions for Omeros. Pacira BioSciences' average media sentiment score of 0.82 beat Omeros' score of 0.47 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Omeros 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, PCRX or OMER? Pacira BioSciences has higher revenue and earnings than Omeros. Pacira BioSciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacira BioSciences$700.97M1.62$41.96M-$2.19-11.17OmerosN/AN/A-$117.81M-$2.70-2.50 Which has more volatility and risk, PCRX or OMER? Pacira BioSciences has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. SummaryPacira BioSciences beats Omeros on 11 of the 18 factors compared between the two stocks. Remove Ads Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMER vs. The Competition Export to ExcelMetricOmerosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$392.51M$6.26B$5.29B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-2.936.7221.6917.68Price / SalesN/A223.16371.6292.88Price / CashN/A65.6738.1534.64Price / Book-16.905.776.373.94Net Income-$117.81M$142.23M$3.20B$247.45M7 Day Performance4.00%2.72%1.67%0.48%1 Month Performance-19.71%-14.04%-9.49%-7.08%1 Year Performance97.08%-12.31%9.59%-0.35% Omeros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMEROmeros3.7314 of 5 stars$6.76-1.6%$22.50+232.8%+97.1%$392.51MN/A-2.93210PCRXPacira BioSciences2.0321 of 5 stars$22.91-0.8%$27.22+18.8%-8.9%$1.06B$700.97M-11.29720NKTRNektar Therapeutics4.097 of 5 stars$0.49-11.1%$4.92+902.6%-59.3%$91.27M$98.43M-0.58220Analyst ForecastGap DownHigh Trading VolumeASMBAssembly Biosciences3.8634 of 5 stars$8.63-0.9%$33.00+282.4%-32.0%$64.75M$28.52M-1.28100Short Interest ↓Gap UpCPIXCumberland Pharmaceuticals1.0314 of 5 stars$4.11-2.8%N/A+190.4%$57.41M$37.87M-5.3480Short Interest ↓Positive NewsGap DownLLYEli Lilly and Company4.9365 of 5 stars$722.03-2.2%$1,009.72+39.8%-1.6%$684.61B$45.04B61.6639,000Analyst ForecastAnalyst RevisionJNJJohnson & Johnson4.7803 of 5 stars$150.47-1.8%$171.33+13.9%+6.6%$362.60B$88.82B22.63152,700Earnings ReportDividend IncreaseAnalyst ForecastShort Interest ↓High Trading VolumeABBVAbbVie4.8987 of 5 stars$186.11-0.5%$211.45+13.6%+5.6%$329.22B$56.33B77.5550,000Analyst RevisionPositive NewsHigh Trading VolumeMRKMerck & Co., Inc.4.9993 of 5 stars$81.11-0.4%$117.12+44.4%-38.9%$204.88B$64.17B12.0569,000Upcoming EarningsHigh Trading VolumePFEPfizer4.9971 of 5 stars$22.64-1.4%$31.92+41.0%-14.2%$128.40B$63.63B16.0683,000High Trading VolumeBMYBristol-Myers Squibb4.7297 of 5 stars$55.18-0.2%$57.86+4.9%+2.2%$112.27B$48.30B-12.4834,300Upcoming EarningsShort Interest ↓Analyst Revision Remove Ads Related Companies and Tools Related Companies PCRX Alternatives NKTR Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OMER) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
